Beijing Konruns Pharmaceutical Co., Ltd. (603590)

Overview

Beijing Konruns Pharmaceutical Co., Ltd., founded in 2003 and headquartered in Beijing, China, operates on a global scale, focusing on the research, development, production, and sale of pharmaceutical products. This company is actively engaged in addressing key healthcare challenges by providing innovative solutions in the realm of clinical hemostatics and cancer treatment among other areas. Through its extensive research and development efforts, Beijing Konruns Pharmaceutical aims to advance medical science and improve patient care worldwide.

Products and Services

• Suling (Agkistrodon acutus hemocoagulase)

  A notable offering under the Suling trade name, this single-component hemocoagulase is a clinical hemostatic drug used extensively in surgical operations to control bleeding. Derived from specific snake venom components, its unique mechanism facilitates clot formation, making surgeries safer and reducing the risk of post-operative complications related to bleeding.

• CX1026

  In the pipeline for addressing cancers affecting the lungs, liver, kidneys, colon, and skin specifically T lymphocyte cancer, CX1026 represents Beijing Konruns Pharmaceutical's commitment to expanding the horizon of cancer treatment. Though details on its mechanism of action remain focused on targeted therapy, CX1026 heralds a new approach to managing complex malignancies.

• CX1003

  Currently undergoing Phase 1 trials, CX1003 is a promising candidate for the treatment of solid tumors, with a preference for rare tumors. This investigational drug underscores the company's dedication to pioneering treatments for less common but highly challenging forms of cancer, potentially offering new hope for patients with limited treatment options.

• ZY5301

  Advancing to Phase 3 clinical trials, ZY5301 targets chronic pelvic pain as a sequel to pelvic inflammatory disease, a condition that significantly impacts the quality of life for many women. By focusing on this specific indication, Beijing Konruns Pharmaceutical addresses a crucial, often neglected area of women's health, showcasing its commitment to broadening treatment options in reproductive health.

• KC-B173

  Designed to manage bleeding and prevent hemorrhage during surgical or invasive procedures, KC-B173 embodies the company's effort to enhance operative safety and reduce perioperative morbidity. This product represents an integral part of the company's portfolio, reflecting its ongoing focus on improving surgical outcomes through innovative pharmacological solutions.

• KC1036

  Undergoing Phase 2 clinical trials, KC1036 is geared towards treating solid tumors. This development signifies Beijing Konruns Pharmaceutical's substantial investment in combatting cancer through novel therapeutic agents, offering potential advancements in the management of malignancies that affect a wide segment of the global population.